Sufentanil Citrate Patent Expiration
Sufentanil Citrate is Used for managing acute pain. It was first introduced by Rising Pharma Holdings Inc
Sufentanil Citrate Patents
Given below is the list of patents protecting Sufentanil Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dsuvia | US10245228 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US10342762 | Small-volume oral transmucosal dosage forms | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US10507180 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US10896751 | Storage and dispensing devices for administration of oral transmucosal dosage forms | Mar 16, 2030 | Vertical Pharms |
| Dsuvia | US11672738 | Apparatus and methods for dispensing oral transmucosal dosage forms | Feb 02, 2038 | Vertical Pharms |
| Dsuvia | US11676691 | Storage and dispensing devices for administration of oral transmucosal dosage forms | Mar 16, 2030 | Vertical Pharms |
| Dsuvia | US8202535 | Small-volume oral transmucosal dosage forms | Oct 22, 2030 | Vertical Pharms |
| Dsuvia | US8226978 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8231900 | Small-volume oral transmucosal dosage | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8252328 | Bioadhesive drug formulations for oral transmucosal delivery | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8252329 | Bioadhesive drug formulations for oral transmucosal delivery | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8535714 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8574189 | Storage and dispensing devices for administration of oral transmucosal dosage forms | Mar 16, 2030 | Vertical Pharms |
| Dsuvia | US8778393 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8778394 | Small-volume oral transmucosal dosage forms | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8865211 | Bioadhesive drug formulations for oral transmucosal delivery | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US8865743 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Oct 22, 2030 | Vertical Pharms |
| Dsuvia | US8945592 | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same | Jul 29, 2031 | Vertical Pharms |
| Dsuvia | US9320710 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
| Dsuvia | US9744129 | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | Jan 05, 2027 | Vertical Pharms |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Sufentanil Citrate Generics
Several generic applications have been filed for Sufentanil Citrate. The first generic version for Sufentanil Citrate was by Watson Laboratories Inc and was approved on Dec 15, 1995. And the latest generic version is by Hospira Inc and was approved on Dec 11, 1996.
Given below is the list of companies who have filed for Sufentanil Citrate generic.
1. WATSON LABS
Watson Laboratories Inc has filed for 1 generic for Sufentanil Citrate. Given below are the details of the strengths of this generic introduced by Watson Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.05MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Dec 15, 1995 |
2. HOSPIRA
Hospira Inc has filed for 1 generic for Sufentanil Citrate. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Dec 11, 1996 |
3. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Sufentanil Citrate. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Dec 15, 1995 |